|
| |
|
|
Advances in antithrombotic prophylaxis and therapy
Vykrutová, Iva ; Tilšer, Ivan (advisor) ; Melicharová, Ludmila (referee)
Thrombotic disease and it's consequences are worlwide one of the leading causes of death. There are prescribed anticoagulants for treatment and prevention. Currently these prescribed drugs - cumarins, unfractioned and fractioned heparins, which have many adverse effects are tried to be replaced. This review is focused on summary informations about two new anticoagulants drug - direct inhibitor f Xa (rivaroxaban) and direct thrombin inhibitor (dabigatran), which could substitude currently used drugs in future. These new substances were clinical tested, where proved safety and efficiency. In these days their indication allow for patients after knee and hip joint replacement. Advantages of rivaroxaban and dabigatran: per os aplication once a day predictable pharmacokinetics and therapeutic response low potencial of drug interaction no needs of monitoring of coagulation Disadvantages of rivaroxaban and dabigatran: limited experience yet significant financial cost unknow antidote In the future these drug could be used for other indications.
|
|
|
Advances in antithrombotic prophylaxis and therapy
Vykrutová, Iva ; Tilšer, Ivan (advisor) ; Melicharová, Ludmila (referee)
Thrombotic disease and it's consequences are worlwide one of the leading causes of death. There are prescribed anticoagulants for treatment and prevention. Currently these prescribed drugs - cumarins, unfractioned and fractioned heparins, which have many adverse effects are tried to be replaced. This review is focused on summary informations about two new anticoagulants drug - direct inhibitor f Xa (rivaroxaban) and direct thrombin inhibitor (dabigatran), which could substitude currently used drugs in future. These new substances were clinical tested, where proved safety and efficiency. In these days their indication allow for patients after knee and hip joint replacement. Advantages of rivaroxaban and dabigatran: per os aplication once a day predictable pharmacokinetics and therapeutic response low potencial of drug interaction no needs of monitoring of coagulation Disadvantages of rivaroxaban and dabigatran: limited experience yet significant financial cost unknow antidote In the future these drug could be used for other indications.
|
|
| |
guest ::
